Kymriah (Tisagenlecleucel) in Pediatric ALL
Pediatric B-cell ALL (Expanded Age Range)
Sponsor Novartis
350 Enrollment Target
80 Trial Sites
5 Countries
December 2028 Est. Completion
About This Trial
Real-world study evaluating CAR-T therapy in broader pediatric population including infants.
Primary Endpoints
- Complete remission rate
- Event-free survival
- Long-term safety
Latest Update
February 2026
92% complete remission rate maintained. FDA approved expanded indication down to age 1 month.